Systemic administration of IL-5 by intraperitoneal injection led to increased IL-5 levels in the CSF of 7-month-old 3xTg-AD mice, indicating that IL-5 can at least partially cross the blood-brain barrier (Fig. 4A). This evidence concerns the gene IL5 and Alzheimer disease.